Lupus Nephritis - Epidemiology Forecast - 2032

DelveInsight's "Lupus Nephritis - Epidemiology Forecast-2032" report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019-2032

Lupus Nephritis Understanding

The DelveInsight’s Lupus Nephritis epidemiology report gives a thorough understanding of Lupus Nephritis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Systemic lupus erythematosus (SLE) is an autoimmune disease that results in chronic inflammation and damage of more than one organ. It is diagnosed clinically and serologically with the presence of autoantibodies. One common and severe manifestation that should be looked for in SLE is the involvement of the kidneys, known as lupus nephritis (LN). Evaluating kidney function in patients suffering from SLE is vital as timely detection and management of renal impairment can greatly improve renal outcomes. LN typically occurs 3 years after and usually within 5 years of the onset of SLE. Histological evidence of LN is present in most SLE patients, even those who do not clinically manifest renal disease.

It can cause many signs and symptoms and may be different for everyone. Signs of lupus nephritis include blood in the urine (hematuria): Glomerular disease can cause the glomeruli to leak blood into the urine. And the urine may look pink or light brown from blood, but most often, they will not be able to see the blood cells except with a microscope. And the protein in the urine (proteinuria): Glomerular disease can cause the glomeruli to leak protein into the urine. The urine may be foamy because of the protein. Edema: Having extra fluid that the kidneys cannot remove that causes swelling in body parts like legs, ankles, or around eyes, etc. And Weight gain due to the fluid in the body cannot get rid of high blood pressure.

Diagnosis

LN is diagnosed through urine and blood tests and a kidney biopsy. One of the first signs of LN is blood in the urine or extremely foamy urine. High blood pressure and swelling in the feet also might indicate lupus nephritis. The blood test measures creatinine, a waste product from the normal breakdown of muscles in the body that is removed from the blood by kidneys.

Lupus Nephritis Epidemiology

The epidemiology section provides insights about the historical and current Lupus Nephritis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.



Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

In the year 2021, the total diagnosed cases of Lupus Nephritis was 209,166 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology [segmented as Total Prevalent Cases of Lupus Nephritis, Total Diagnosed Cases of Lupus Nephritis, Total Treated Cases of Lupus Nephritis] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Lupus Nephritis Epidemiology

The epidemiology segment also provides the Lupus Nephritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

KOL- Views

To keep up with the current Lupus Nephritis patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Lupus Nephritis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report
The report covers the descriptive overview of Lupus Nephritis, explaining their causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Lupus Nephritis.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by total Prevalent Cases of Lupus Nephritis, total Diagnosed Cases of Lupus Nephritis and total treated Cases of Lupus Nephritis

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Lupus Nephritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lupus Nephritis
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Lupus Nephritis Report Key Strengths
11 Years Forecast
7MM Coverage
Lupus Nephritis Epidemiology Segmentation

Key Questions



Epidemiology Insights:
What are the disease risk, burden, and regional/ethnic differences of Lupus Nephritis?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical Lupus Nephritis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Lupus Nephritis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM concerning the patient population about Lupus Nephritis?
Out of all 7MM countries, which country would have the highest prevalent population of Lupus Nephritis during the forecast period (2019-2032)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?



Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Lupus Nephritis Disease market
To understand the future market competition in the Lupus Nephritis Disease market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Lupus Nephritis Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for the Lupus Nephritis Disease market
To understand the future market competition in the Lupus Nephritis Disease market